Piramal to hike research spend for cancer drugs' trials

摘要

Piramal Healthcare's research and development (R&D) spend will significantly rise this fiscal year as it looks to initiate the second phase of clinical trials for at least two oncology molecules, its head of research, Mr. Somesh Sharma said. The drugmaker, which spent about Rs. 121-crore on R&D in nine months to December last year, will see expenditure jumping to Rs. 200-crore in FY12-13. Piramal Healthcare has completed the phase-! trials for its tumour suppressor molecule P1446A-05, while its blood cancer treatment molecule P2745 is in the last stages of first phase trials.